Vaxneuvance increases presence in NIP mkt
By Hwang, Byung-woo | translator Alice Kang
24.08.07 12:04:00
가나다라
0
Since its release in April, Vaxneuvance has shown double-digit growth in the market
Market share of initial dose higher, cross-dosing from 13-valent to 15-valent vaccine is also rising
A follow-up vaccine to Vaxneuvance is expected to be released in the second half of the year... Competition depends on 'vaccine’s scope of coverage + immunogenicity'
MSD Korea is accelerating its efforts to capture the national immunization program (NIP) market by touting the high immunogenicity of Vaxneuvance.
The vaccine has already been rapidly introduced to general hospitals and clinics upon its launch, and the company is highlighting the vaccine’s clinical benefits to gain a competitive advantage.
▲Dr. Hyun-mi Kang, Professor of Pediatrics, St. Mary
Vaxneuvance, which was approved late last year, is the first new pneumococcal vaccine introduced to Korea in 13 years. It is a 15-valent vaccine that added 2 serotypes -22F and 33F – to the existing 13-valent vaccine.
In particular, the vaccine made the pediatric NIP list at an unprecedented speed, just one month after its
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)